Astellas offers $379M buyout for a pioneering stem cell survivor – FierceBiotech
Xconomy |
Astellas offers $379M buyout for a pioneering stem cell survivor
FierceBiotech Astellas Pharma has stepped up with a $379 million bid for Ocata Therapeutics, a pioneering–and often controversial–stem cell company that has managed to survive a years-long roller coaster ride through the hype, hope and disappointments of the past … With $379M Deal For Ocata, Astellas Buys Stem Cells For Eye Diseases Marlborough stem cell pioneer Ocata attracts buyout bid for nearly double its … Astellas Pharma to buy stem cell pioneer Ocata |
